KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non Operating Income (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Non Operating Income for 15 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 59.35% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.3 million, a 18.21% decrease, with the full-year FY2025 number at $13.3 million, down 18.21% from a year prior.
  • Other Non Operating Income was $2.0 million for Q4 2025 at Supernus Pharmaceuticals, down from $2.3 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $14.7 million in Q1 2022 to a low of -$21.5 million in Q4 2021.
  • A 5-year average of $2.4 million and a median of $2.7 million in 2021 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 478.28% in 2021, then tumbled 63.63% in 2023.
  • Supernus Pharmaceuticals' Other Non Operating Income stood at -$21.5 million in 2021, then surged by 111.14% to $2.4 million in 2022, then decreased by 17.25% to $2.0 million in 2023, then soared by 150.6% to $5.0 million in 2024, then plummeted by 59.35% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Other Non Operating Income are $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $4.5 million (Q2 2025).